Table 2.

Disease-Free Survival Hazard Ratios Adjusted for Number of positive nodes for Chemotherapy Benefit by Recurrence Score over Time

	All Years		First 5 years		After 5 years
Modeled HR estimates	HR	95% CI	HR	95% CI	HR	95% CI
Nodes (4+)	2.44	1.75–3.42	2.49	1.58–3.92	2.37	1.44–3.91
Chemotherapy at RS=0	1.12	0.61–2.06	1.58	0.66–3.76	0.78	0.34–1.83
RS/50 (50 point difference)	2.71	1.37–5.36	5.77	2.42–13.79	0.92	0.30–2.83
Chemo* RS/50	0.43	0.18–1.01	0.30	0.10–0.89	0.66	0.16–2.82
Interaction p-value	(0.053 )	-	(0.029)	-	(0.58)	-
Treatment effect overall*	HR	95% CI	HR	95% CI	HR	95% CI
Entire RS sample	0.72	0.51 – 1.00	0.79	0.51–1.23	0.63	0.39–1.04
At selected RS values
RS = 10	0.95	0.59–1.52	1.24	0.62–2.48	0.72	0.38–1.36
RS = 18	0.83	0.56–1.22	1.03	0.58–1.81	0.67	0.40–1.14
RS = 25	0.74	0.53–1.04	0.87	0.53–1.42	0.64	0.39–1.05
RS = 31	0.67	0.48–0.93	0.75	0.48–1.18	0.61	0.35–1.04
RS = 40	0.57	0.39–0.83	0.61	0.38–0.96	0.56	0.28–1.11

^*Benefit in disease-free survival of CAF added to tamoxifen versus tamoxifen alone